利匹韦林浓度-反应模型在HIV-1初治与经治患者中的研究
本研究在60例初治和39例经治HIV-1感染者中建立利匹韦林群体药效学模型,估算EC50为65 ng/mL,经治患者CD4感染速率常数更高、病毒学抑制时间更长,提示现行50 ng/mL谷浓度疗效靶值可能需上调。
要点
- 利匹韦林群体EC50估计为65 ng/mL。
- 经治患者CD4感染速率常数高于初治患者。
- 经治患者达到病毒学抑制的时间更长。
核心结论
- 利匹韦林浓度-反应关系首次通过群体药效学模型得到满意描述。
- 模拟显示现行50 ng/mL谷浓度疗效靶值可能需上调,尤其经治患者。
研究设计与样本
- 回顾性观察研究,纳入每日一次利匹韦林/替诺福韦二吡呋酯/恩曲他滨方案患者。
- 共60例初治和39例经治患者,随访2至37个月。
- 用既往药代模型预测个体利匹韦林谷血浆浓度,以易感-感染-恢复模型描述HIV动态,MONOLIX 2018行群体分析。
主要发现
- 最终模型良好描述数据,药效学参数估计精度良好。
- 利匹韦林EC50群体典型值为65 ng/mL。
- 经治患者CD4细胞HIV-1感染速率常数高于初治患者。
- 经治患者获得病毒学抑制的时间长于初治患者。
关键数值与推荐
- 利匹韦林EC50群体典型值为65 ng/mL。
- 现行利匹韦林谷血浆浓度疗效靶值为50 ng/mL,模型提示可能需上调。
临床怎么用
- 临床可参考EC50 65 ng/mL理解利匹韦林暴露-效应关系。
- 对经治患者应关注谷浓度是否足够,现行50 ng/mL靶值可能偏低。
局限性
- 谷浓度由既往药代模型预测而非直接测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rilpivirine is widely prescribed in people living with HIV. Although trough plasma concentrations have been associated with virological response, the drug pharmacodynamics remain incompletely characterized. OBJECTIVES: To develop the first pharmacodynamic model of rilpivirine in order to establish the rilpivirine concentration-response relationship for future treatment optimization. METHODS: A retrospective observational study was conducted in patients receiving the once-daily rilpivirine/tenofovir disoproxil fumarate/emtricitabine regimen. Individual rilpivirine trough plasma concentrations over time were predicted using a previous pharmacokinetic model. An established susceptible, infected, recovered model was used to describe HIV dynamics without assuming disease steady-state. Population analysis was performed with MONOLIX 2018 software. Simulations of the viral load evolution as a function of time and rilpivirine trough plasma concentration were performed. RESULTS: Overall, 60 naive and 39 pre-treated patients were included with a follow-up ranging from 2 to 37 months. The final model adequately described the data and the pharmacodynamic parameters were estimated with a good precision. The population typical value of rilpivirine EC50 was estimated at 65 ng/mL. A higher infection rate constant of CD4 cells for HIV-1 was obtained in pre-treated patients. Consequently, the time to obtain virological suppression was longer in pre-treated than in naive patients. CONCLUSIONS: The concentration-response relationship of rilpivirine was satisfactorily described for the first time using an original population pharmacodynamic model. Simulations performed using the final model showed that the currently used 50 ng/mL rilpivirine trough plasma concentration efficacy target might need revision upwards, particularly in pre-treated patients.
引用
- Néant N, Solas C, Bouazza N, et al. Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. J Antimicrob Chemother. 2019. PMID: 31225609. doi:10.1093/jac/dkz141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。